158 related articles for article (PubMed ID: 32710011)
1.
Tuazon SA; Sandmaier BM; Gooley TA; Fisher DR; Holmberg LA; Becker PS; Lundberg SJ; Orozco JJ; Gopal AK; Till BG; Coffey DG; Nartea ME; Matesan MC; Pagel JM; Rajendran JG; Press OW; Bensinger WI; Green DJ
Bone Marrow Transplant; 2021 Jan; 56(1):202-209. PubMed ID: 32710011
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
Fasslrinner F; Stölzel F; Kramer M; Teipel R; Brogsitter C; Morgner A; Arndt C; Bachmann M; Hänel M; Röllig C; Kotzerke J; Schetelig J; Bornhäuser M
Biol Blood Marrow Transplant; 2020 Apr; 26(4):691-697. PubMed ID: 31730919
[TBL] [Abstract][Full Text] [Related]
3. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
4. Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.
Vo P; Gooley TA; Rajendran JG; Fisher DR; Orozco JJ; Green DJ; Gopal AK; Haaf R; Nartea M; Storb R; Appelbaum FR; Press OW; Pagel JM; Sandmaier BM
Haematologica; 2020 Jun; 105(6):1731-1737. PubMed ID: 31582553
[TBL] [Abstract][Full Text] [Related]
5. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.
Mawad R; Gooley TA; Rajendran JG; Fisher DR; Gopal AK; Shields AT; Sandmaier BM; Sorror ML; Deeg HJ; Storb R; Green DJ; Maloney DG; Appelbaum FR; Press OW; Pagel JM
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1363-8. PubMed ID: 24858425
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
11. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
Maloney DG; Molina AJ; Sahebi F; Stockerl-Goldstein KE; Sandmaier BM; Bensinger W; Storer B; Hegenbart U; Somlo G; Chauncey T; Bruno B; Appelbaum FR; Blume KG; Forman SJ; McSweeney P; Storb R
Blood; 2003 Nov; 102(9):3447-54. PubMed ID: 12855572
[TBL] [Abstract][Full Text] [Related]
12. A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Grüllich C; Bertz H; Spyridonidis A; Müller CI; Finke J
Bone Marrow Transplant; 2008 May; 41(10):845-50. PubMed ID: 18209719
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
Bashir Q; Khan H; Thall PF; Liu P; Shah N; Kebriaei P; Parmar S; Oran B; Ciurea S; Nieto Y; Jones R; Hosing CM; Popat UR; Dinh YT; Rondon G; Orlowski RZ; Shah JJ; De Lima M; Shpall E; Champlin R; Giralt S; Qazilbash MH
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1453-8. PubMed ID: 23872222
[TBL] [Abstract][Full Text] [Related]
14. Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of Transplantation.
Kliman D; Nivison-Smith I; Gottlieb D; Hamad N; Kerridge I; Purtill D; Szer J; Ma D
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1711-1718. PubMed ID: 32194285
[TBL] [Abstract][Full Text] [Related]
15. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
18. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation as consolidation immunotherapy of cancer after autologous transplantation.
Maris MB; Storb R
Acta Haematol; 2005; 114(4):221-9. PubMed ID: 16269862
[TBL] [Abstract][Full Text] [Related]
20. Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.
Schneidawind C; Duerr-Stoerzer S; Faul C; Kanz L; Weisel K; Bethge W; Schneidawind D
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28470884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]